Sanofi Consumer Healthcare India logo

Sanofi Consumer Healthcare India MD, chairman, board of directors and AGM

NSE: SANOFICONRBSE: 544250Pharmaceuticals & BiotechnologySmall Cap

Last close ₹3,207.90down ₹54.90 (1.68%)BSE ₹3,212.45

Share price at the NSE close on 23 Oct 2026. Previous close ₹3,262.80.

52-week range of traded prices to 23 Oct 2026
₹3,200.00Low, 23 Oct 2026₹5,255.00High, 14 May 2026
Market cap
₹7,388 Cr551st largest listed
P/E
27.8
P/B
21.2
Dividend yield
2.34%
ROE
87.9%
ROCE
97.6%
Debt to equity
0.00
Volume, NSE
15,77169.2% delivered

Sanofi Consumer Healthcare India board of directors

At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

  • ChairpersonAMIT JAIN
  • Managing directorHIMANSHU BAKSHI
  • Company Secretary and Compliance OfficerNikunjkumar Savaliya

6 directors3 independent1 executive2 non-executive

  • AMIT JAIN · ChairpersonIndependent · joined Mar 2024 · reappointed Mar 2024 · 28 months as independent · 3 listed boards · 3 as independent · 1 committee seat
  • SHOBINDER DUGGALIndependent · joined Mar 2024 · reappointed Mar 2024 · 28 months as independent · 4 listed boards · 4 as independent · 6 committee seats, 4 as chair
  • SUPARNA PANDHIIndependent · joined Mar 2024 · reappointed Mar 2024 · 28 months as independent · 2 listed boards · 2 as independent · 1 committee seat
  • CAROL-ANN STEWARTNon-executive · joined Jun 2023 · 1 listed board
  • STANISLAS MARIE JEAN PAUL CAMARTNon-executive · joined Aug 2024 · 1 listed board · 2 committee seats
  • HIMANSHU BAKSHI · Managing directorExecutive · joined Jun 2024 · 1 listed board · 1 committee seat

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

2 directors who left
  • MAITHILEE KAIZAD MISTRY, left 5 May 2025: Others
  • SURENDRA AGARWALL, left 31 Dec 2024: Others

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 25 May 20266 of 6 present3 independent · 26 days in between
    • 28 Apr 20265 of 6 present2 independent · 61 days in between
    • 25 Feb 20266 of 6 present3 independent

  • Audit Committee

    Chair SHOBINDER DUGGAL

    SUPARNA PANDHI, STANISLAS MARIE JEAN PAUL CAMART

    • 25 May 20263 of 3 present2 independent · 26 days in between
    • 28 Apr 20263 of 3 present2 independent · 62 days in between
    • 24 Feb 20263 of 3 present2 independent

  • Nomination and remuneration committee

    Chair SUPARNA PANDHI

    AMIT JAIN, CAROL-ANN STEWART

    • 25 Feb 20263 of 3 present2 independent

  • Stakeholders Relationship Committee

    Chair SHOBINDER DUGGAL

    HIMANSHU BAKSHI, STANISLAS MARIE JEAN PAUL CAMART

    No meeting listed in the filing.

  • Risk Management Committee

    Chair AMIT JAIN

    HIMANSHU BAKSHI, STANISLAS MARIE JEAN PAUL CAMART

    • 19 Mar 20263 of 3 present1 independent · 21 days in between

  • Corporate Social Responsibility Committee

    Chair SUPARNA PANDHI

    HIMANSHU BAKSHI, STANISLAS MARIE JEAN PAUL CAMART

    • 24 Feb 20263 of 3 present1 independent

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Jun 2026.

  • Price Waterhouse & Co Chartered Accountants LLPPeer-review certificate valid to Nov 2026
1 earlier auditor
  • Kalyaniwalla & Mistry LLPNamed in filings from Mar 2025 to Mar 2026

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Sanofi Consumer Healthcare India AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Sanofi Consumer Healthcare India dividend history

Annual general meeting, 26 Jun 2026

49,698 shareholders on the register on 19 Jun 2026; present: 2 promoters and 52 others; votes counted by Omkar Dindorkar / MMJB & Associates LLP.The company's voting result (opens in a new tab)

  1. To receive, consider and adopt the Annual Audited Standalone Financial Statements of the Company for the year ended 31st December 2025, including the Balance Sheet as on 31st December 2025, the Statement of Profit and Loss and the Cash Flow Statement for the Financial Year ended on that date and Reports of Board of Directors and Auditors thereon.MoreLess
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.25%

    Turnout: all 89.59% · promoters 100.00% · institutions 89.54% · other public 0.31%

  2. To declare a final dividend of Rs. 75 per equity share of Rs. 10 each for the Financial Year ended 31st December 2025
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.24%

    Turnout: all 89.59% · promoters 100.00% · institutions 89.54% · other public 0.31%

  3. To re-appoint Mr. Stanislas Camart, (DIN: 10686945) as Director, who retires by rotation and being eligible, offers himself for re-appointment.
    Ordinary
    99.88% for0.12% against

    Against: promoters 0.00% · institutions 0.60% · other public 1.39%

    Turnout: all 89.59% · promoters 100.00% · institutions 89.54% · other public 0.31%

  4. Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP (Firm Registration No.: 304026E/ E300009) as the Statutory Auditors of the Company.
    Ordinary
    91.28% for8.72% against

    Against: promoters 0.00% · institutions 42.72% · other public 1.70%

    Turnout: all 89.59% · promoters 100.00% · institutions 89.54% · other public 0.31%

  5. Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP (Firm Registration No.: 304026E/E300009) as the Statutory Auditors of the Company to fill the casual vacancy.
    Ordinary
    99.50% for0.50% against

    Against: promoters 0.00% · institutions 2.45% · other public 2.93%

    Turnout: all 89.59% · promoters 100.00% · institutions 89.54% · other public 0.31%

  6. Ratification of remuneration to Cost Auditors.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 1.10%

    Turnout: all 89.59% · promoters 100.00% · institutions 89.54% · other public 0.31%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 22 Apr 2026, 4 resolutions

50,742 shareholders on the register on 20 Mar 2026; votes counted by Omkar Dindorkar / MMJB & Associates LLP.The company's voting result (opens in a new tab)

  1. Approval for material related party transactions with Opella Healthcare India Private Limited
    OrdinaryPromoters have an interest in it
    99.95% for0.05% against

    Against: promoters 0.00% · institutions 0.00% · other public 10.55%

    Turnout: all 19.59% · promoters 0.00% · institutions 95.88% · other public 1.14%

  2. Approval for material related party transactions with Opella Healthcare International SAS
    OrdinaryPromoters have an interest in it
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.00% · other public 12.05%

    Turnout: all 19.59% · promoters 0.00% · institutions 95.88% · other public 1.13%

  3. Approval of overall limits of remuneration payable to Non-Executive Director(s)
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 6.98%

    Turnout: all 90.86% · promoters 100.00% · institutions 95.88% · other public 1.13%

  4. To consider and approve the amendment to the terms of remuneration of Mr. Himanshu Bakshi (DIN: 08188412), Managing Director, to enable participation in the Incentive Plan
    Ordinary
    99.98% for0.02% against

    Against: promoters 0.00% · institutions 0.07% · other public 5.38%

    Turnout: all 90.86% · promoters 100.00% · institutions 95.88% · other public 1.13%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 29 Oct 2025, 2 resolutions

51,137 shareholders on the register on 26 Sep 2025; votes counted by Omkar Dindorkar / MMJB & Associates LLP.The company's voting result (opens in a new tab)

  1. Approval for material related party transactions with Opella Healthcare India Private Limited
    OrdinaryPromoters have an interest in it
    99.87% for0.13% against

    Against: promoters 0.00% · institutions 0.00% · other public 33.08%

    Turnout: all 19.37% · promoters 0.00% · institutions 95.81% · other public 0.89%

  2. Approval for material related party transactions with Opella Healthcare International SAS
    OrdinaryPromoters have an interest in it
    99.87% for0.13% against

    Against: promoters 0.00% · institutions 0.00% · other public 34.23%

    Turnout: all 19.37% · promoters 0.00% · institutions 95.81% · other public 0.86%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 5 May 2025, 7 resolutions

53,563 shareholders on the register on 28 Apr 2025; present: 1 promoter and 49 others; votes counted by Omkar Dindorkar / MMJB & Associates LLP.The company's voting result (opens in a new tab)

  1. To receive, consider and adopt the Annual Audited Standalone financial statements of the Company for the financial year ended 31st December 2024, including the Balance Sheet as on December 31, 2024, the Statement of Profit and Loss and the Cash Flow Statement for the Financial Year ended on that date and Reports of the Board of Directors and the Auditors thereonMoreLess
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 88.13% · promoters 100.00% · institutions 92.39% · other public 0.22%

  2. To declare a final dividend of ₹ 55/- per Equity shares of ₹ 10 each for the financial year ended December 31, 2024
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 88.13% · promoters 100.00% · institutions 92.39% · other public 0.22%

  3. To re-appoint Ms. Carol-Ann Stewart, (DIN: 10194751) as Director, who retires by rotation and being eligible, offers herself for re-appointment.
    Ordinary
    99.89% for0.11% against

    Against: promoters 0.00% · institutions 0.35% · other public 0.66%

    Turnout: all 88.13% · promoters 100.00% · institutions 92.39% · other public 0.22%

  4. To re-appoint Mr. Himanshu Bakshi (DIN: 08188412) as Director, who retires by rotation and being eligible, offers himself for re-appointment.
    Ordinary
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.20% · other public 0.84%

    Turnout: all 88.13% · promoters 100.00% · institutions 92.39% · other public 0.22%

  5. Ratification of remuneration to Cost Auditors
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.02%

    Turnout: all 88.13% · promoters 100.00% · institutions 92.39% · other public 0.22%

  6. Appointment of Secretarial Auditor
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 88.13% · promoters 100.00% · institutions 92.39% · other public 0.22%

  7. Payment of Commission to Non-Executive Directors of the Company
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 8.52%

    Turnout: all 88.13% · promoters 100.00% · institutions 92.39% · other public 0.22%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 29 Mar 2025, 5 resolutions

56,220 shareholders on the register on 21 Feb 2025; votes counted by Omkar Dindorkar / MMJB & Associates LLP.The company's voting result (opens in a new tab)

  1. Appointment of Ms. Maithilee Mistry (DIN: 02152619) as a Director ofthe Company
    Ordinary
    99.89% for0.11% against

    Against: promoters 0.00% · institutions 0.25% · other public 17.66%

    Turnout: all 88.88% · promoters 100.00% · institutions 93.42% · other public 1.43%

  2. Appointment of Ms. Maithilee Mistry (DIN: 02152619) as Whole-time Director of the Company
    Ordinary
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.09% · other public 17.40%

    Turnout: all 88.88% · promoters 100.00% · institutions 93.42% · other public 1.43%

  3. Approval for material related party transactions with Sanofi India Limited
    OrdinaryPromoters have an interest in it
    99.90% for0.10% against

    Against: promoters 0.00% · institutions 0.00% · other public 16.85%

    Turnout: all 22.82% · promoters 0.00% · institutions 74.76% · other public 1.43%

  4. Approval for material related party transactions with Opella Healthcare India Private Limited
    OrdinaryPromoters have an interest in it
    99.90% for0.10% against

    Against: promoters 0.00% · institutions 0.00% · other public 17.19%

    Turnout: all 22.82% · promoters 0.00% · institutions 74.76% · other public 1.43%

  5. Approval for material related party transactions with Opella Healthcare International SAS
    OrdinaryPromoters have an interest in it
    99.90% for0.10% against

    Against: promoters 0.00% · institutions 0.00% · other public 17.70%

    Turnout: all 22.82% · promoters 0.00% · institutions 74.76% · other public 1.43%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 12 Dec 2024, 4 resolutions

The company's voting result (opens in a new tab)

  1. Appointment of Mr. Himanshu Bakshi (DIN: 08188412) as a Director of the Company
    Ordinary
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.10% · other public 8.74%

    Turnout: all 86.93% · promoters 100.00% · institutions 90.09% · other public 0.98%

  2. Appointment of Mr. Himanshu Bakshi (DIN: 08188412) as Managing Director of the Company
    Ordinary
    99.97% for0.03% against

    Against: promoters 0.00% · institutions 0.06% · other public 8.76%

    Turnout: all 86.93% · promoters 100.00% · institutions 90.09% · other public 0.97%

  3. Appointment of Mr. Stanislas Camart (DIN: 10686945) as a Director of the Company
    Ordinary
    99.80% for0.20% against

    Against: promoters 0.00% · institutions 0.63% · other public 8.91%

    Turnout: all 86.93% · promoters 100.00% · institutions 90.09% · other public 0.98%

  4. Approval for material related party transactions with Sanofi India Limited
    OrdinaryPromoters have an interest in it
    93.92% for6.08% against

    Against: promoters 0.00% · institutions 6.06% · other public 10.56%

    Turnout: all 20.65% · promoters 0.00% · institutions 70.04% · other public 0.96%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.Funds that hold it

Mutual fund votes, meeting of 26 Jun 2026, 14 fund houses

  • To receive, consider and adopt the Annual Audited Standalone Financial Statements of the Company for the year ended 31st December 2025, including the Balance Sheet as on 31st December 2025, the Statement of Profit and Loss and the Cash Flow Statement for the Financial Year ended on that date and Reports of Board of Directors and Auditors thereon.MoreLess
    14 for0 against
  • To declare a final dividend of Rs. 75 per equity share of Rs. 10 each for the Financial Year ended 31st December 2025
    14 for0 against
  • To re-appoint Mr. Stanislas Camart, (DIN: 10686945) as Director, who retires by rotation and being eligible, offers himself for re-appointment.
    14 for0 against
  • Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP (Firm Registration No.: 304026E/ E300009) as the Statutory Auditors of the Company.
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Groww Mutual Fund, Mirae Asset Mutual Fund, Motilal Oswal Mutual Fund, Nippon India Mutual Fund, SBI Mutual Fund, Sundaram Mutual Fund
    • Angel One Mutual FundGovernance Concern: The Company was incorporated as a result of demerged of the Consumer Healthcare business of Sanofi India Limited (SIL) and the auditors have been associated with SIL since 2017; hence the proposed appointment of Statutory auditors until the 8th AGM (to be held in 2031) will lead to prolonged association of the auditors with the Company.
    • Bandhan Mutual Fund, Groww Mutual FundCompliant with law. No concern identified on the merits of the proposed Statutory Auditor. Governance Concern: The Company was incorporated as a result of demerged of the Consumer Healthcare business of Sanofi India Limited (SIL) and the auditors have been associated with SIL since 2017; hence the proposed appointment of Statutory auditors until the 8th AGM (to be held in 2031) will lead to prolonged association of the auditors with the Company.
    • Baroda BNP Paribas Mutual FundAs the appointment is till the 8th AGM i.e. 2031 the tenure will be more than 10 years (2017 to 2031). Long association may compromise auditor independence.
    • Mirae Asset Mutual FundAs per advisory recommendation (Passive holding)
    • Motilal Oswal Mutual FundProlonged association of the auditors with the Company.
    • Nippon India Mutual FundGovernance Concern: The proposed auditor appointment until 2031 would result in prolonged association, given their prior engagement with Sanofi India Limited since 2017, raising independence concerns.
    • SBI Mutual Fund, Sundaram Mutual FundAt the 2024 AGM, Kalyaniwalla & Mistry LLP were appointed as the statutory auditors of the company for five years. However, via their letter dated 30 April 2026, Kalyaniwalla & Mistry LLP resigned citing low audit fees. The board proposes to appoint Price Waterhouse & Co. in place of Kalyaniwalla & Mistry LLP, for a period of five years from the conclusion of 2026 AGM. We note that Price Waterhouse & Co. have served as the statutory auditor of Sanofi India Limited since the 2017 AGM. If the proposed appointment is approved, their aggregate association with the group will exceed ten years. Given the extended association of the auditor with group companies, we believe the appointment is not in keeping with the spirit of Section 139 of the Companies Act, 2013, which expects auditors to be rotated every 10 years. We do not support the resolution.
    5 for9 against
  • Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP (Firm Registration No.: 304026E/E300009) as the Statutory Auditors of the Company to fill the casual vacancy.
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund
    • Angel One Mutual FundGovernance Concern: The Company was incorporated as a result of demerged of the Consumer Healthcare business of Sanofi India Limited (SIL) and the auditors have been associated with SIL since 2017; hence the proposed appointment of Statutory auditors until the 8th AGM (to be held in 2031) will lead to prolonged association of the auditors with the Company.
    • Bandhan Mutual Fund, Groww Mutual FundCompliant with law. No concern identified on the merits of the proposed Statutory Auditor. Governance Concern: The Company was incorporated as a result of demerged of the Consumer Healthcare business of Sanofi India Limited (SIL) and the auditors have been associated with SIL since 2017; hence the proposed appointment of Statutory auditors until the 8th AGM (to be held in 2031) will lead to prolonged association of the auditors with the Company.
    • Motilal Oswal Mutual FundProlonged association of the auditors with the Company.
    10 for4 against
  • Ratification of remuneration to Cost Auditors.
    14 for0 against

Mutual fund votes, meeting of 22 Apr 2026, 14 fund houses

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • Approval for material related party transactions with Opella Healthcare India Private Limited
    14 for0 against
  • Approval for material related party transactions with Opella Healthcare International SAS
    14 for0 against
  • To consider and approve the amendment to the terms of remuneration of Mr. Himanshu Bakshi (DIN: 08188412), Managing Director, to enable participation in the Incentive Plan
    14 for0 against
3 proposals not matched to one resolution
  • 3) Approve payment of commission to Non-Executive Directors upto 1% of net profits for five years from 1 January 2025.
    1 for0 against
  • Approve payment of commission to Non-Executive Directors upto 1% of net profits for five years from 1 January 2025
    3 for0 against
  • To pay its Non-Executive Directors, other than the Managing Director or Whole-time Director(s) or Director(s) who are employees of Sanofi or companies of the Group, in addition to sitting fees paid to them for attending the meetings of the Board of Directors or its Committees, such sum by way of commission, every year for a period of five financial years commencing from January 1, 2025, as the Board may determine from time to time, but not exceeding 1% (one percent) or such other percentage of the Net Profits of the Company in any financial year.MoreLess
    10 for0 against
4 earlier meetings

Mutual fund votes, meeting of 29 Oct 2025, 14 fund houses

  • Approval for material related party transactions with Opella Healthcare India Private Limited
    14 for0 against
  • Approval for material related party transactions with Opella Healthcare International SAS
    14 for0 against

Mutual fund votes, meeting of 5 May 2025, 15 fund houses

  • To receive, consider and adopt the Annual Audited Standalone financial statements of the Company for the financial year ended 31st December 2024, including the Balance Sheet as on December 31, 2024, the Statement of Profit and Loss and the Cash Flow Statement for the Financial Year ended on that date and Reports of the Board of Directors and the Auditors thereonMoreLess
    15 for0 against
  • To declare a final dividend of ₹ 55/- per Equity shares of ₹ 10 each for the financial year ended December 31, 2024
    15 for0 against
  • To re-appoint Ms. Carol-Ann Stewart, (DIN: 10194751) as Director, who retires by rotation and being eligible, offers herself for re-appointment.
    15 for0 against
  • To re-appoint Mr. Himanshu Bakshi (DIN: 08188412) as Director, who retires by rotation and being eligible, offers himself for re-appointment.
    15 for0 against
  • Ratification of remuneration to Cost Auditors
    15 for0 against
  • Appointment of Secretarial Auditor
    15 for0 against
  • Payment of Commission to Non-Executive Directors of the Company
    15 for0 against

Mutual fund votes, meeting of 29 Mar 2025, 10 fund houses

  • Appointment of Ms. Maithilee Mistry (DIN: 02152619) as a Director ofthe Company
    10 for0 against
  • Appointment of Ms. Maithilee Mistry (DIN: 02152619) as Whole-time Director of the Company
    10 for0 against
  • Approval for material related party transactions with Sanofi India Limited
    10 for0 against
  • Approval for material related party transactions with Opella Healthcare India Private Limited
    10 for0 against
  • Approval for material related party transactions with Opella Healthcare International SAS
    10 for0 against

Mutual fund votes, meeting of 12 Dec 2024, 12 fund houses

  • Appointment of Mr. Himanshu Bakshi (DIN: 08188412) as a Director of the Company
    11 for0 against
  • Appointment of Mr. Himanshu Bakshi (DIN: 08188412) as Managing Director of the Company
    11 for0 against
  • Appointment of Mr. Stanislas Camart (DIN: 10686945) as a Director of the Company
    11 for0 against
  • Approval for material related party transactions with Sanofi India Limited
    Against Bajaj Finserv Mutual Fund, PGIM India Mutual Fund
    • Bajaj Finserv Mutual FundCompliant with law. Governance Concern: Basis for Arm’s Length pricing is not disclosed. "Subsequent to the demerger of Sanofi India Limited and its Consumer Healthcare business, the Company primarily transacts with SIL for purchase of goods and availing toll manufacturing and other support services, among others. Since SIL is already in possession of the required licenses, the Company’s association with SIL helps it to continue its operations efficiently and achieve its business objectives. SIL being a related party, approval is being sought for the above mentioned transactions for the aggregate outstanding value of all such material related party transactions/contracts/ arrangements not exceeding Rs. 1,050 Million (Rupees One Thousand Fifty Millions only) during the year ending on 31st December, 2024, by way of this resolution. However in case of RPTs prior approval has to be sought. Keeping in mind the company got listed in September 2024 and company has proposed approval within three months of its listing on stock exchange we are not raising any concerns. Further it is to be noted that the Company has merely stated in the explanatory statement that the RPTs are at arm’s length basis,however, it has not provided any disclosure regarding the basis of arriving at the same. We understand that Audit Committee must be having a rationale for considering the RPT to be at Arm’s Length basis, similarly, such rationale should also be disclosed for shareholders’ information and decision making. Since the company has not disclosed the Basis for Arm’s length pricing. and without a basis for arm's length pricing, it is not feasible to determine the fairness of the transaction. "
    • PGIM India Mutual FundCompliant with law. Governance Concern: Basis for Arm s Length pricing is not disclosed
    10 for2 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

None open at any quarter's end.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
Yes
The chair is related to the managing director
No
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
No
There was a cyber security incident in the quarter
No

The company's own answers in its filing.

How money raised was used

The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it.